TLPH (Talphera Corporation) Projected Price to Earnings

Official company branding of Talphera Corp (TLPH)

Can Talphera, Inc. (TLPH) overcome limited margins driven by high regulatory costs? The non-cyclical nature of biotech development provides resilience to GDP, and the GURU.Markets portal features a forward P/E ratio chart for Talphera, Inc. (TLPH), where the latest parameter is 0.00. The asset's ultimate stability currently depends on attracting investment and the success of clinical drug trials.

TLPH - Talphera Market Cap to Projected Earnings over the range 02/21/2024 - 11/10/2026

Analytical breakdowns for Talphera, Inc.

- current price and projected stock value:
Stock Quotes Talphera|TLPH - Fair Value Consensus
- business market valuation indicators:
Market Valuation Talphera Inc|TLPH - Total Company Value
- issuer book value statistics:
Book Value per Share Talphera|TLPH - Book Valuation of Business|Market Value to Book Value Ratio talphera.com|TLPH - Aggregate Asset Value
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Talphera, Inc.|TLPH - Long-Term Debt to Capital|Short-Term Debt to Equity Talphera, Inc.|TLPH - Company Total Debt Obligations|Debt to Book Value Talphera Inc|TLPH - Amount of Long-Term Liabilities|Company Short-Term Debts Talphera|Quick Liquidity talphera.com
- earnings and market ratios statistics:
TLPH - Company Net Income|Expected Profit Talphera, Inc.|TLPH - Market Cap to Net Income|Forward P/E Multiple Talphera Corp|TLPH - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Talphera Inc|TLPH - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Talphera|TLPH - Earnings per share for the trailing year|Quarterly EPS earnings growth talphera.com|TLPH - Earnings growth in current year|Expected earnings per share growth for next year Talphera, Inc.
Basic company analysis:Talphera TLPH
Product sample of Talphera, Inc.

Sales of sublingual pain management systems in US hospitals form the foundation of the cash flow for Talphera, Inc. (TLPH), making the valuation of future earnings critically important. By analyzing the company's current forward P/E, an investor compares the market value of the stock with projected annual income, identifying whether the asset is overbought or possesses hidden growth potential upon the implementation of new product lines.

Key competitors

Projected Price to Earnings GILD (Gilead Sciences)|CDTX (Cidara Therapeutics) - Future Price to Earnings Multiple|Novavax Corp - Projected Price to Earnings|CureVac Pharma - Future Price to Earnings|Valneva SE - Forward P/E Multiple|Market Cap to Projected Earnings vir.bio VIR|SIGA Technologies (SIGA) - Future Price to Earnings|Emergent BioSolutions Inc - Future Price to Earnings Multiple|Projected Price to Earnings AVIR|Forward P/E Multiple Invivyd Corp|Future Price to Earnings Enanta Pharmaceuticals (ENTA)|Market Cap to Projected Earnings inovio.com|HilleVax - Projected Price to Earnings|Market Cap to Future Earnings Ratio KLRS (Kalaris Therapeutics Inc.)|Dyadic - Forward P/E Multiple|NNVC - Forward P/E Multiple|Cocrystal Pharma, Inc. (COCP) - Future Price to Earnings|TRAW (Traws Pharma) - Future Price to Earnings|Future Price to Earnings Dogwood Therapeutics Inc.|Qualigen Therapeutics Inc - Price to Expected Earnings Ratio|Forward P/E Multiple ALVR|VBIV (vbivaccines.com) - Future Price to Earnings Multiple|Forward P/E Multiple VIRI (Virios Therapeutics, Inc.)|Vaxart Inc. (VXRT) - Projected Price to Earnings Ratio